AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
CAPItello Efficacy: rPFS Improvement
Karim Fizazi presents significant rPFS benefit and a 7.5-month median improvement with capivasertib.
Play episode from 40:59
Transcript
